Bajaj Healthcare shares hit new 52-week high after receiving DRDO nod to manufacture, sell its COVID-19 drug

Bajaj Healthcare said in a regulatory filing that it has received a licence from Defence Research and Development Organisation (DRDO) to Manufacture and Market of ‘2-Deoxy-D-Glucose’ as approved medication for the treatment of COVID-19 patients.